Literature DB >> 16102942

Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients.

Sonia Dollfus1, Véronique Olivier, Benoît Chabot, Cécile Déal, Elena Perrin.   

Abstract

OBJECTIVE: To compare the efficacy of two atypical antipsychotic drugs, olanzapine and risperidone, in schizophrenic patients with post-psychotic depression.
RESULTS: A clinically significant decrease of MADRS scores occurred in patients treated with both drugs for 8 weeks.
CONCLUSION: Atypical antipsychotic drugs may be particularly appropriate when treating schizophrenic patients with depression.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16102942     DOI： 10.1016/j.schres.2005.06.001

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


  7 in total

1.  Agomelatine for Depression in Schizophrenia: A Case-Series.

Authors:  Jochen Mutschler; Nicolas Rüsch; Herdis Schönfelder; Uwe Herwig; Annette B Brühl; Martin Grosshans; Wulf Rössler; Heike Russmann
Journal:  Psychopharmacol Bull       Date:  2012-02-15

Review 2.  Olanzapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Lorna Duggan; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

3.  Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.

Authors:  Shinichiro Nakajima; Hiroyoshi Takeuchi; Gagan Fervaha; Eric Plitman; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Yukiko Mihashi; Philip Gerretsen; Gary Remington; Benoit Mulsant; Ariel Graff-Guerrero
Journal:  Schizophr Res       Date:  2014-12-30       Impact factor: 4.939

Review 4.  Risperidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Sandra Schwarz; Franziska Schmid; Heike Hunger; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

5.  Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.

Authors:  Hoda Moteshafi; Simon Zhornitsky; Sarah Brunelle; Emmanuel Stip
Journal:  Drug Saf       Date:  2012-10-01       Impact factor: 5.606

6.  A composite scale applied to evaluate anxiety in schizophrenic patients (SAES).

Authors:  Pierre-Michel Llorca; Christophe Lancon; Olivier Blanc; Ingrid de Chazeron; Ludovic Samalin; Hervé Caci; Jean-Alexandre Lesturgeon; Franck J Bayle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-06-15       Impact factor: 5.270

7.  Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies.

Authors:  Henry A Nasrallah; Josephine B Cucchiaro; Yongcai Mao; Andrei A Pikalov; Antony D Loebel
Journal:  CNS Spectr       Date:  2014-06-23       Impact factor: 3.790
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.